The SGC catalyses research in new areas of human biology and drug discovery by focusing explicitly on less well-studied areas of the human genome. The SGC accelerates research in these new areas by making all its research output available to the scientific community with no strings attached, and by creating an open collaborative network of scientists in hundreds of universities around the world and in eight global pharmaceutical companies. Together, this network of academic and industry scientists is driving a new scientific and drug discovery ecosystem whose primary aim is to advance science and is less influenced by personal, institutional or commercial gain. The SGC operates from seven academic institutions worldwide - the University of Toronto, Oxford University, UNICAMP, University of North Carolina-Chapel Hill, Karolinska Institute, Goethe University Frankfurt and the Montreal Neurological Institute (The Neuro).
